A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease.
about
Erythropoietin or darbepoetin for patients with cancerDrug therapy for the management of cancer-related fatigueErythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient dataDrug therapy for the management of cancer related fatigueErythropoietin for patients with malignant diseaseErythropoietin or Darbepoetin for patients with cancerDarbepoetin alfa: a new approach to the treatment of chemotherapy-induced anaemia.Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia.Pharmacotherapy of chemotherapy-induced anaemia.Evaluation of the US Oncology Network's recommended guidelines for therapeutic substitution with darbepoetin alfa 200 microg every 2 weeks in both naïve patients and patients switched from epoetin alfa.Darbepoetin alfa for the treatment of cancer-related anemia: an update.Strategies to optimize the use of erythropoietin and iron therapy in oncology patients.The use of darbepoetin alfa for the treatment of chemotherapy-induced anaemia.Anaemia in cancer patients: pathophysiology, incidence and treatment.Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.Current and future options for the treatment of chemotherapy-induced anaemia.Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes.Effectiveness of darbepoetin alfa in a cohort of oncology patients with chemotherapy-induced anaemia. Relationship between variation in three fatigue-specific quality of life questionnaire scores and change in haemoglobin level.Single dose darbepoetin alfa is useful in reducing red cell transfusions in leukemic children receiving chemotherapy.Cost-effectiveness of epoetin alfa and darbepoetin alfa in patients with chemotherapy-related anemia.Pharmacologic interventions for fatigue in cancer and transplantation: a meta-analysis.
P2860
Q24202335-2EB0BCCA-1F27-4948-864A-59DD245CA475Q24234267-DAAB6C4E-18B4-48C0-BD62-2307ECFD5FB4Q24240202-E5F09A51-652D-4261-86A2-D9345388763EQ24242050-B8FB02FA-7A63-4FD8-B0D6-48A27AEFFE45Q24245427-ED1DDDEC-9707-4BE3-9576-D1433B1BB71BQ24245464-F0900FAF-FBE8-44C4-B585-223E3E9C3565Q35144050-DBE73D1B-3463-47E2-A5FD-807401B515F5Q35166812-2A8C4C48-C115-490E-8C09-BBB1F7A7C4C4Q35593977-AB0EDB61-5B9D-4334-95BA-47998FBF73A6Q35709723-607F24C3-F5C5-411C-8A02-D82C7D9D6E06Q35918431-E60CDA99-8B50-45D2-9D12-3D7B6FB24169Q35976513-2C00F12F-88EE-4A7A-8BE7-3C204931241EQ36082066-E1E1BED8-7248-4CEE-9577-E34D8E00FFE0Q36310891-D14BAF82-0B0F-439B-8081-7AF7B5A5AD18Q36333136-F38188DF-CFCC-4B97-99B1-C6F21B3BC8E2Q36568736-1D940407-57A5-45A5-95A0-EA6E2D69DF31Q45215891-D079F14C-A697-42EC-B2DF-6025460C741CQ48666474-F91B3C73-80A1-4A13-9693-053C561DBCD9Q50485217-CA1F2F0D-E2BD-4842-B303-8619C55FE3DAQ50759560-9DA98EBE-0667-4FC5-B2E8-7473F15B44B3Q52714644-2146F9BB-B563-419E-97B8-04B7530B4DE3
P2860
A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
A randomized, active-control, ...... therapy for malignant disease.
@en
type
label
A randomized, active-control, ...... therapy for malignant disease.
@en
prefLabel
A randomized, active-control, ...... therapy for malignant disease.
@en
P2093
P356
P1433
P1476
A randomized, active-control, ...... therapy for malignant disease.
@en
P2093
Alan B Colowick
Alex Fleishman
Glen Justice
Gregory Rossi
Jaswant Sinh Jadeja
John A Glaspy
P304
P356
10.1002/CNCR.11186
P407
P577
2003-03-01T00:00:00Z